🔺 What to do when markets are at an all-time high? Find smart bargains, like these.See Undervalued Stocks

Alteogen Inc (196170)

KOSDAQ
Currency in KRW
308,000
-10,000(-3.14%)
Closed
196170 Scorecard
Full Analysis
Net income is expected to grow this year
Fair Value
Day's Range
306,500317,500
52 wk Range
66,100455,500
Key Statistics
Edit
Bid/Ask
308,000.00 / 308,500.00
Prev. Close
318,000
Open
317,500
Day's Range
306,500-317,500
52 wk Range
66,100-455,500
Volume
638.68K
Average Volume (3m)
888.53K
1-Year Change
327.79%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
196170 Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Price Target
476,667.00
Upside
+54.76%
Members' Sentiments
Bearish
Bullish
ProTips
Analysts anticipate sales decline in the current year
Show more

Alteogen Inc Company Profile

ALTEOGEN Inc., a bio company, focuses on developing long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars. The company develops ALT-P1, a long-acting human growth hormone that is in the Phase IIa clinical trial; and ALT-Q2, a long-acting active form of coagulation factor VII for the treatment of hemophilia based on its NexP technology. It is also involved in the development of ALT-P7, a targeted breast/gastric cancer drug that is in the Phase I clinical trial; ALT-Q5, an antibody-drug conjugate (ADC) for the treatment of ovarian cancer based on its NexMab ADC technology; and ALT-LS2, a SC (subcutaneous) formulation of trastuzuamb for the treatment of breast and gastric cancer. The company has a strategic alliance with Kissei Pharmaceutical for the development of ALT-L9, a biosimilar of Eylea (Aflibercept) which is currently under Phase 1 trial; and Cristalia for the development of ALT-L2, a biosimilar of Herceptin (Trastuzumab), a monoclonal antibody for the treatment of breast cancer, which is in the Phase II clinical trial. ALTEOGEN Inc. was founded in 2008 and is headquartered in Daejeon, South Korea.

Employees
128

Compare 196170 to Peers and Sector

Metrics to compare
196170
Peers
Sector
Relationship
P/E Ratio
−5,620.6x−8.3x−0.7x
PEG Ratio
35.350.040.00
Price/Book
92.1x2.4x2.6x
Price / LTM Sales
219.6x19.2x3.2x
Upside (Analyst Target)
29.9%32.5%47.1%
Fair Value Upside
Unlock5.0%7.3%Unlock

Analysts' Recommendations

3 Buy
0 Hold
0 Sell
Ratings:
3 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 476,667

(+54.76% Upside)

People Also Watch

109,900
141080
-1.17%
171,800
000660
+0.82%
33,100
042660
+4.09%
116,600
000100
-0.93%
298,000
012450
+2.41%

FAQ

What Is the Alteogen (196170) Stock Price Today?

The Alteogen stock price today is 308,000.00

What Stock Exchange Does Alteogen Trade On?

Alteogen is listed and trades on the KOSDAQ stock exchange.

What Is the Stock Symbol for Alteogen?

The stock symbol for Alteogen is "196170."

What Is the Alteogen Market Cap?

As of today, Alteogen market cap is 15.19T.

What is Alteogen Earnings Per Share?

The Alteogen EPS is -55.08.

What Is the Next Alteogen Earnings Date?

Alteogen will release its next earnings report on Apr 06, 2025.

From a Technical Analysis Perspective, Is 196170 a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Sell.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.